NUCB2 and neoplasm: Interestingly, the implication of Nucb2/nesfatin-1 in CACS was shown by Burgos et al. [57]; their studies were conducted on a tumor-bearing murine model with implanted methylcholanthrene-induced sarcoma (MCG101), which is a low or undifferentiated epithelial-like solid tumor with high expression of prostaglandin E2 [58].